Michael Bien is a Nephrology physician affiliated with Centers for Disease Control and Prevention. OpenAlex indexes 13 publications with 380 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1335 W Cypress Ave
Suite # 205
San Dimas, CA 917733537
Telephone
909-542-2770Registry record last updated 16 Mar 2012.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- AKEBIA THERAPEUTICS INCProgram year20253 payments
- Amgen Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.4%Calcium channel blocker11.4%Amlodipine Besylate67%Nifedipine Er33%Part D≥56 patientsBeta blocker10%Atenolol30%Carvedilol29%Metoprolol Succinate27%Metoprolol Tartrate8%Labetalol Hcl7%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
17.3%Vitamin D3 Analog4.8%Calcitriol76%Rayaldee25%Part D<11 patientsProton pump inhibitor4.2%Pantoprazole Sodium49%Dexlansoprazole Dr26%Omeprazole-Sodium Bicarbonate26%Part D<11 patients+ 10 more classes in this area
Other
13.2%Phosphate Binder7.2%Sevelamer Hcl54%Sevelamer Carbonate46%Part D≥40 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia6%Lokelma43%Velphoro34%Auryxia23%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lessons Learned from COVID-19 Response in Correctional and Detention Facilities
Emerging infectious diseases
2024 - What We (Don’t) Know About the Infectious Disease Burden Among Youth Experiencing Homelessness in the United States and Canada
The Journal of Infectious Diseases
2024 - Lessons Learned from COVID-19 Response in Correctional and Detention Facilities
Emerging infectious diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Alicia Fry
Centers for Disease Control and Prevention
Matthew D. Ritchey
Centers for Disease Control and Prevention
Marc Fischer
Centers for Disease Control and Prevention
Lorenzo Botto, MD
Centers for Disease Control and Prevention
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”